But old style phone regulations often require network operators to maintain and expand obsolete copper wires and TDM (time division multiplexing) switching technologies.
This morning, Roche announced that the Food and Drug Administration refused to consider the application for the TDM-1 breast cancer drug based on technology that it licensed from Immunogen, a Waltham, Mass. biotechnology company.